Cancer Fighters Thrive® 10109 E. 79th Street Tulsa, OK 74133
SANCUSO®
(Granisetron Transdermal System):
A recommendation from leading treatment guidelines1,2
When preparing for chemotherapy be
armed ready
& For nausea and vomiting
One patch. One application. 5 days of coverage.3
Visit www.sancuso.com to learn more and to download a money- saving co-pay card.
Please refer to the sunlight warning in the important safety information below.
Important safety information SANCUSO®
chemotherapy regimens of up to 5 consecutive days duration.4 components of the patch.4
(Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the Mild application site reactions
Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.4
have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.4 artifi cial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.4 SANCUSO is constipation (5.4%).4
SANCUSO contains granisetron.4
Patients should avoid direct exposure of application site to natural or The most common adverse reaction in patients receiving
Healthcare professionals should avoid prescribing any additional products that contain granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.4
References: 1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V.1.2012. http://www.nccn.org/ professionals/physician_gls/pdf/antiemesis.pdf. Accessed December 13, 2011. 2. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011;29(31):4189-4198. 3. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; on behalf of the Sancuso Study Group. Effi cacy and tolerability of transdermal granisetron for the control of chemotherapy- induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10):1609-1617. 4. SANCUSO [package insert]. BRIDGEWATER, NJ: ProStrakan, Inc; 2011.
www.prostrakan-usa.com www.sancuso.com
SANCUSO is a registered trademark of ProStrakan, Inc. ©2012 ProStrakan, Inc. All rights reserved. Printed in U.S.A. SAN-2012-006 February 2012
Please see brief summary of Prescribing Information on adjacent page.
Keeps them covered
ONLY